Dermata Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 26, 2026

DRMA$0.77+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Cash Flows

	For the year ended December 31,
2025 · 2024
Cash flows from operating activities:
Net loss		$(7,558,557)	$(12,287,461)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		143,732	657,649
Increase (decrease) in cash resulting from changes in:
Prepaid expenses and other current assets		30,470	168,181
Accounts payable		(388,056)	(108,512)
Accrued and other current liabilities		14,852	407,195
Net cash used in operating activities		(7,757,559)	(11,162,948)
Cash flows from financing activities:
Proceeds from issuance of Common Stock, pre-funded warrants, and warrants, net of issuance costs		12,167,852	6,886,102
Payment of prior period issuance costs		(50,495)	-
Proceeds from exercise of pre-funded warrants		977	1,109
Payment for fractional shares in reverse stock split		(367)	(828)
Net cash provided by financing activities		12,117,967	6,886,383
Net increase (decrease) in cash and cash equivalents		4,360,408	(4,276,565)
Cash and cash equivalents at beginning of period		3,161,570	7,438,135
Cash and cash equivalents at end of period		$7,521,978	$3,161,570
Supplemental disclosure:
Cash paid for taxes		$950	$950
Non-cash financing activities:
Issuance of abeyance shares	$	-	$(18)
Issuance costs in accounts payable or accrued expenses		$91,352	$50,495

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.